Aeterna Zentaris to Announce Third Quarter 2010 Financial and Operating Results on November 9, 2010

QUÉBEC CITY, Nov. 4 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") will announce its third quarter 2010 financial and operating results on Tuesday, November 9, 2010. The Company will host a conference call and webcast to discuss these results later that same day at 4:00 p.m., Eastern Time.

Participants may access the live webcast via the Company's website at www.aezsinc.com in the "Newsroom" section, or by telephone using the following numbers: in Canada, 514-807-9895 or 647-427-7450, outside Canada, 888-231-8191. A replay of the webcast will also be available on the Company's website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian, endometrial cancer and multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing the Company with constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com.



SOURCE AETERNA ZENTARIS INC.

Suggested Articles

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.

Lilly has created customized mobile research units to run the clinical trial as the long-term care facilities lack experience running studies.